Tags

Type your tag names separated by a space and hit enter

Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients.
Int J Clin Pract. 2006 Sep; 60(9):1060-7.IJ

Abstract

The aim of this study was to evaluate the tolerability, safety and efficacy of pregabalin in Indian patients with peripheral neuropathic pain. In this prospective, multicenter, non-comparative, open-label study, patients with peripheral neuropathic pain (n = 111) received pregabalin in doses ranging from 75 to 300 mg twice daily for 3 weeks. Primary efficacy measures included weekly pain score and the Visual Analogue Scale (VAS) score of the Short-Form McGill Pain Questionnaire (SF-MPQ). Despite a short study duration, a significant reduction was seen in weekly pain score (p < 0.0001), as well as VAS score of SF-MPQ (p < 0.0001). Significant improvements were also seen in other pain-related endpoints, weekly sleep interference score, quality of life measures, and patient and clinician ratings of global improvement. Pregabalin was well tolerated, and the most common adverse events were dizziness and somnolence. The short study duration precluded the assessment of longer term safety issues such as weight gain. This study has demonstrated the safety, tolerability and efficacy of pregabalin for peripheral neuropathic pain in Indian patients.

Authors

No affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16939547

Citation

LYRICA Study Group. "Pregabalin for Peripheral Neuropathic Pain: Results of a Multicenter, Non-comparative, Open-label Study in Indian Patients." International Journal of Clinical Practice, vol. 60, no. 9, 2006, pp. 1060-7.
LYRICA Study Group. Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients. Int J Clin Pract. 2006;60(9):1060-7.
LYRICA Study Group. (2006). Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients. International Journal of Clinical Practice, 60(9), 1060-7.
LYRICA Study Group. Pregabalin for Peripheral Neuropathic Pain: Results of a Multicenter, Non-comparative, Open-label Study in Indian Patients. Int J Clin Pract. 2006;60(9):1060-7. PubMed PMID: 16939547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients. A1 - ,, PY - 2006/8/31/pubmed PY - 2007/4/27/medline PY - 2006/8/31/entrez SP - 1060 EP - 7 JF - International journal of clinical practice JO - Int J Clin Pract VL - 60 IS - 9 N2 - The aim of this study was to evaluate the tolerability, safety and efficacy of pregabalin in Indian patients with peripheral neuropathic pain. In this prospective, multicenter, non-comparative, open-label study, patients with peripheral neuropathic pain (n = 111) received pregabalin in doses ranging from 75 to 300 mg twice daily for 3 weeks. Primary efficacy measures included weekly pain score and the Visual Analogue Scale (VAS) score of the Short-Form McGill Pain Questionnaire (SF-MPQ). Despite a short study duration, a significant reduction was seen in weekly pain score (p < 0.0001), as well as VAS score of SF-MPQ (p < 0.0001). Significant improvements were also seen in other pain-related endpoints, weekly sleep interference score, quality of life measures, and patient and clinician ratings of global improvement. Pregabalin was well tolerated, and the most common adverse events were dizziness and somnolence. The short study duration precluded the assessment of longer term safety issues such as weight gain. This study has demonstrated the safety, tolerability and efficacy of pregabalin for peripheral neuropathic pain in Indian patients. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/16939547/Pregabalin_for_peripheral_neuropathic_pain:_results_of_a_multicenter_non_comparative_open_label_study_in_Indian_patients_ L2 - https://doi.org/10.1111/j.1742-1241.2006.01069.x DB - PRIME DP - Unbound Medicine ER -